Chimerix (NASDAQ:CMRX) Share Price Passes Above 200-Day Moving Average - What's Next?

Chimerix, Inc. (NASDAQ:CMRX - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.91 and traded as high as $1.00. Chimerix shares last traded at $0.99, with a volume of 207,019 shares traded.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. StockNews.com raised shares of Chimerix from a "sell" rating to a "hold" rating in a research report on Wednesday, August 21st. Wedbush restated an "outperform" rating and set a $6.00 price target on shares of Chimerix in a research note on Tuesday, August 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $11.00 price objective on shares of Chimerix in a research note on Wednesday, August 14th.

Chimerix Stock Performance

The company has a market capitalization of $88.74 million, a PE ratio of -1.04 and a beta of 1.12. The company's 50-day simple moving average is $0.90 and its 200-day simple moving average is $0.91.

Chimerix (NASDAQ:CMRX - Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.23). The company had revenue of $0.13 million for the quarter, compared to analysts' expectations of $1.26 million. During the same period in the prior year, the business earned ($0.21) EPS. Analysts expect that Chimerix, Inc. will post -0.86 EPS for the current year.

Institutional Investors Weigh In On Chimerix

Large investors have recently modified their holdings of the stock. Marshall Wace LLP purchased a new position in Chimerix during the second quarter worth about $137,000. Valeo Financial Advisors LLC boosted its stake in shares of Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company's stock valued at $76,000 after buying an additional 69,505 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Chimerix by 15.5% during the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company's stock worth $2,304,000 after acquiring an additional 291,981 shares during the period. Koshinski Asset Management Inc. purchased a new position in Chimerix in the first quarter worth $42,000. Finally, Marquette Asset Management LLC lifted its holdings in Chimerix by 24.3% in the first quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company's stock valued at $123,000 after acquiring an additional 22,709 shares during the period. Hedge funds and other institutional investors own 45.42% of the company's stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.